The overall aim of this investigation is to establish whether an action of Xyrem® on the
brain dopamine system in patients with narcolepsy, and in a comparison control group, might
explain part of the anti-narcoleptic effect of the drug.
Trial Objective is to establish, using positron emission tomography (PET), in Xyrem®-naïve
narcolepsy with cataplexy patients, and in matched controls, whether a single dose of Xyrem®
causes changes in striatal binding of 11C-raclopride and 11C-DTBZ that would suggest altered
activity of brain dopamine neurones.